Breaking News Instant updates and real-time market news.

ALDR

Alder Biopharmaceuticals

$11.50

0.07 (0.61%)

08:15
07/11/19
07/11
08:15
07/11/19
08:15

Alder to present data from open-label Phase 3 PREVAIL trial at AHS meeting

Alder will unveil a visual representation of eptinezumab that enriches the understanding of how the molecule was designed to interact with high specificity and strong binding to the CGRP ligand, which may contribute to the rapid onset of efficacy and sustained prevention observed in the clinical trials. Other key posters to be presented at the meeting include additional quality of life data showing early and sustained improvements in the HIT-6 impact rating total score in patients with chronic migraine in the PROMISE-2 trial, as well as data from the open-label Phase 3 PREVAIL trial showing reduction of migraine disability for patients with chronic migraine treated with eptinezumab. Safety and tolerability were evaluated in all the eptinezumab clinical trials with no serious adverse drug reactions related to eptinezumab identified within the clinical trial program. The U.S. Food and Drug Administration accepted the Biologics License Application for eptinezumab in April 2019 and set a Prescription Drug User Fee Act target action date of February 21, 2020. If approved, eptinezumab will be the first-to-market intravenous (IV) therapy for migraine prevention.

  • 09

    Sep

  • 21

    Feb

ALDR Alder Biopharmaceuticals
$11.50

0.07 (0.61%)

04/04/19
PIPR
04/04/19
NO CHANGE
PIPR
Overweight
Piper Jaffray stays Overweight on Alder Biopharma, Amgen after Novartis filing
Piper Jaffray analyst Christopher Raymond maintains his Overweight rating on Alder Biopharma (ALDR) and Amgen (AMGN) after the filing by Novartis (NVS) alleging legal dispute with the latter about their migraine collaboration. The analyst says that Novartis tried to beat Amgen to the punch after entering agreement with Alder to manufacture eptinezumab, which prompted Amgen to terminate their commercialization agreement. Raymond adds that a resolution of this dispute could take a year or more but believes that investors may conclude that the spat reflects the value of anti-CGRP assets.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."
05/28/19
LEER
05/28/19
INITIATION
Target $21
LEER
Outperform
Alder Biopharmaceuticals initiated with an Outperform at SVB Leerink
SVB Leerink analyst Marc Goodman initiated Alder Biopharmaceuticals with an Outperform and $21 price target.
07/10/19
FBCO
07/10/19
INITIATION
Target $14
FBCO
Neutral
Alder Biopharmaceuticals assumed with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman assumed coverage of Alder Biopharmaceuticals with a Neutral rating and $14 price target.

TODAY'S FREE FLY STORIES

ADAP

Adaptimmune

$3.43

0.1 (3.00%)

07:15
07/19/19
07/19
07:15
07/19/19
07:15
Conference/Events
Adaptimmunemanagement to meet with Piper Jaffray »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 29

    Jul

  • 29

    Jul

  • 30

    Jul

  • 31

    Jul

HQY

HealthEquity

$76.39

0.96 (1.27%)

, WAGE

WageWorks

$50.79

-0.01 (-0.02%)

07:14
07/19/19
07/19
07:14
07/19/19
07:14
Upgrade
HealthEquity, WageWorks rating change  »

BofA sees 'too many…

HQY

HealthEquity

$76.39

0.96 (1.27%)

WAGE

WageWorks

$50.79

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHM

Autohome

$82.03

-0.91 (-1.10%)

07:12
07/19/19
07/19
07:12
07/19/19
07:12
Downgrade
Autohome rating change  »

Benchmark downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLF

Cleveland-Cliffs

$10.88

-0.11 (-1.00%)

07:12
07/19/19
07/19
07:12
07/19/19
07:12
Hot Stocks
Cleveland-Cliffs expects to reach commercial production at Toledo HBI in 1H20 »

Cliffs now expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 06

    Aug

ATRA

Atara Biotherapeutics

$15.27

0.25 (1.66%)

07:10
07/19/19
07/19
07:10
07/19/19
07:10
Syndicate
Atara Biotherapeutics 6.87M share Spot Secondary priced at $15.28 »

Citi, Goldman Sachs and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFS

Discover

$81.65

1.62 (2.02%)

07:10
07/19/19
07/19
07:10
07/19/19
07:10
Hot Stocks
Discover names Jennifer Wong to board »

Discover announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 13

    Nov

CLF

Cleveland-Cliffs

$10.88

-0.11 (-1.00%)

07:10
07/19/19
07/19
07:10
07/19/19
07:10
Hot Stocks
Cleveland-Cliffs backs FY19 sales volume guidance of 20M long tons »

Backs FY19 production…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 06

    Aug

GRUB

GrubHub

$74.90

0.17 (0.23%)

07:09
07/19/19
07/19
07:09
07/19/19
07:09
Initiation
GrubHub initiated  »

GrubHub initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 06

    Aug

07:05
07/19/19
07/19
07:05
07/19/19
07:05
General news
FX Update: The dollar settled at firmer levels »

FX Update: The dollar…

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

07:04
07/19/19
07/19
07:04
07/19/19
07:04
Recommendations
Intuitive Surgical analyst commentary  »

Intuitive Surgical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 09

    Sep

IBKC

Iberiabank

$75.24

0.8 (1.07%)

07:04
07/19/19
07/19
07:04
07/19/19
07:04
Earnings
Iberiabank reports Q2 non-GAAP EPS $1.87, consensus $1.82 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 23

    Sep

CLF

Cleveland-Cliffs

$10.88

-0.11 (-1.00%)

07:04
07/19/19
07/19
07:04
07/19/19
07:04
Hot Stocks
Cleveland-Cliffs reports Q2 sales volume 6.2M long tons »

Reports Q2 production…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 06

    Aug

SLB

Schlumberger

$38.78

0.15 (0.39%)

07:04
07/19/19
07/19
07:04
07/19/19
07:04
Earnings
Schlumberger reports Q2 ex-items EPS 35c, consensus 35c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 27

    Aug

  • 13

    Nov

HALO

Halozyme

$16.79

0.03 (0.18%)

, JNJ

Johnson & Johnson

$132.03

0.21 (0.16%)

07:02
07/19/19
07/19
07:02
07/19/19
07:02
Hot Stocks
Halozyme: Janssen submits extension application to EMA for DARZALEX »

Halozyme (HALO) announced…

HALO

Halozyme

$16.79

0.03 (0.18%)

JNJ

Johnson & Johnson

$132.03

0.21 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

CLF

Cleveland-Cliffs

$10.88

-0.11 (-1.00%)

07:02
07/19/19
07/19
07:02
07/19/19
07:02
Earnings
Cleveland-Cliffs reports Q2 EPS 57c, consensus 52c »

Reports Q2 revenue $743M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 06

    Aug

KBR

KBR

$25.28

0.36 (1.44%)

07:01
07/19/19
07/19
07:01
07/19/19
07:01
Upgrade
KBR rating change  »

KBR upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

ROK

Rockwell Automation

$159.17

-0.78 (-0.49%)

07:00
07/19/19
07/19
07:00
07/19/19
07:00
Recommendations
Rockwell Automation analyst commentary  »

JPMorgan's Tusa says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SXT

Sensient

$70.77

-0.48 (-0.67%)

07:00
07/19/19
07/19
07:00
07/19/19
07:00
Earnings
Sensient lowers 2019 adjusted EPS view to down 8%-9% from down 4%-7% »

Consensus for 2019 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

MSFT

Microsoft

$136.29

0.06 (0.04%)

06:58
07/19/19
07/19
06:58
07/19/19
06:58
Recommendations
Microsoft analyst commentary  »

Microsoft price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

BLK

BlackRock

$474.98

4.06 (0.86%)

06:58
07/19/19
07/19
06:58
07/19/19
06:58
Hot Stocks
BlackRock CEO: Trend in China continues to be downward »

Says: Companies are not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 27

    Oct

MSFT

Microsoft

$136.29

0.06 (0.04%)

06:57
07/19/19
07/19
06:57
07/19/19
06:57
Recommendations
Microsoft analyst commentary  »

Microsoft price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

CNK

Cinemark

$36.46

-1.31 (-3.47%)

06:57
07/19/19
07/19
06:57
07/19/19
06:57
Initiation
Cinemark initiated  »

Cinemark initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SXT

Sensient

$70.77

-0.48 (-0.67%)

06:56
07/19/19
07/19
06:56
07/19/19
06:56
Earnings
Sensient reports Q2 EPS 81c, consensus 82c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

EYE

National Vision

$32.05

0.35 (1.10%)

06:56
07/19/19
07/19
06:56
07/19/19
06:56
Hot Stocks
National Vision names Melissa Rasmussen as Chief Accounting Officer »

National Vision announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWD

Crowdstrike

$72.75

1.77 (2.49%)

06:55
07/19/19
07/19
06:55
07/19/19
06:55
Recommendations
Crowdstrike analyst commentary  »

Crowdstrike price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.